A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients with Axial Spondyloarthritis


Trials Status

Founded by physicians in 2006, LCTC Inc., provides an attractive source for conducting phase III-IV clinical research funded by Pharmaceutical, Biotech Companies, Contract Research Organizations or NIH funded trials.
Latin Clinical Trial Center
1801 Ponce de Leon Ave,
Suite 205, San Juan, PR 00909
787-249-4763 (24/7)
Fax: 787-982-7100
© 2023 Latin Clinical Trial Center. All Rights Reserved.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram